Farther Finance Advisors LLC Purchases 21 Shares of argenx SE (NASDAQ:ARGX)

Farther Finance Advisors LLC grew its stake in shares of argenx SE (NASDAQ:ARGX) by 38.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76 shares of the company’s stock after buying an additional 21 shares during the period. Farther Finance Advisors LLC’s holdings in argenx were worth $47,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in ARGX. Whipplewood Advisors LLC bought a new stake in argenx in the 4th quarter worth $37,000. Global Retirement Partners LLC boosted its stake in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after purchasing an additional 61 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in argenx during the fourth quarter worth about $66,000. Finally, Nkcfo LLC bought a new stake in argenx during the fourth quarter worth about $68,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ARGX shares. Piper Sandler boosted their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. HC Wainwright boosted their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a report on Friday, February 28th. Oppenheimer boosted their price objective on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. William Blair reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Stock Up 0.3 %

argenx stock opened at $615.02 on Monday. The company has a market cap of $37.37 billion, a price-to-earnings ratio of -698.89 and a beta of 0.59. The firm’s fifty day moving average is $634.69 and its 200 day moving average is $600.25. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities research analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.